Natural and hybrid ("chimeric") stable regulatory glyproline peptides.
Review of earlier studies · 2005
- What was studied
- Developer synthesis of glyprolin research
- Main finding
- The developers described PGP-containing hybrid peptides as a way to combine regulatory activity with greater peptide stability. This historical framework does not transfer Semax or Selank outcomes to isolated PGP.
Study data at a glance
- Participants or experimental model
- Developer synthesis of glyprolin research
- Reported results
- The developers described PGP-containing hybrid peptides as a way to combine regulatory activity with greater peptide stability. This historical framework does not transfer Semax or Selank outcomes to isolated PGP.
Study limitations and source details
Study limitations
- Review of a research program, not an independent trial.
- Specific peptide origin, metabolism and clinical claims require original-source confirmation.
Source details
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Abstract reviewed
Sources checked
Citation
Ashmarin IP, Samonina GE, Lyapina LA, Kamenskii AA, Levitskaya NG, Grivennikov IA, Dolotov OV, Andreeva LA, Myasoedov NF. Natural and hybrid ("chimeric") stable regulatory glyproline peptides. Pathophysiology : the official journal of the International Society for Pathophysiology
Study source ↗ · DOI 10.1016/j.pathophys.2004.10.001 · Bibliography entry · Link to this summary
Related compounds
Glyprolins & PGP hybrids
A family of short peptides rich in glycine and proline, including PGP and experimental peptides built by adding PGP to another sequence.
Semax
A synthetic heptapeptide, Met–Glu–His–Phe–Pro–Gly–Pro (MEHFPGP). It combines residues 4–7 of adrenocorticotropic hormone (ACTH) with Pro–Gly–Pro and has been studied in ischemic stroke.
Selank
A synthetic heptapeptide, Thr–Lys–Pro–Arg–Pro–Gly–Pro (TKPRPGP). It extends the immune peptide tuftsin with Pro–Gly–Pro and has been studied in anxiety and neurobiology.